Article
Public, Environmental & Occupational Health
Michael D. George, Jesse Y. Hsu, Sean Hennessy, Lang Chen, Fenglong Xie, Jeffrey R. Curtis, Joshua F. Baker
Summary: A study conducted on patients with rheumatoid arthritis found an increased risk of infection requiring hospitalization associated with low-dose glucocorticoid use. This finding was confirmed using both instrumental variable (IV) analysis and traditional analysis methods.
Review
Immunology
Uday Raj Sharma, Akhila Nediyedath Rathnakaran, B. P. Prudhvi Raj, Gayathry Padinjakkara, Akanksh Das, Surendra Vada, Manjunatha P. Mudagal
Summary: Rheumatoid arthritis is an autoimmune inflammatory disorder characterized by joint destruction and symmetrical symptoms. Pregnancy has a positive effect on RA, with different hypotheses explaining this. Treatment options for RA include the use of DMARDs and NSAIDs.
INFLAMMOPHARMACOLOGY
(2021)
Article
Rheumatology
Delila Singh, Nina Hesse, Alla Skapenko, Hendrik Schulze-Koops
Summary: Methotrexate is associated with rare bone lesions that are often misdiagnosed as osteoporotic fractures. Early diagnosis is crucial for treatment and prevention of further osteopathology. This case highlights the importance of raising awareness and taking appropriate therapeutic measures, including discontinuing methotrexate.
Article
Radiology, Nuclear Medicine & Medical Imaging
Yasser Abdelhafez, Siba P. Raychaudhuri, Dario Mazza, Soumajyoti Sarkar, Heather L. Hunt, Kristin McBride, Mike Nguyen, Denise T. Caudle, Benjamin A. Spencer, Negar Omidvari, Heejung Bang, Simon R. Cherry, Lorenzo Nardo, Ramsey D. Badawi, Abhijit J. Chaudhari
Summary: This study evaluated the performance of an ultra-low-dose 18F-FDG TB PET/CT acquisition protocol in assessing systemic joint involvement in AIA, and the correlation between TB PET/CT measures and rheumatologic evaluation. The results showed that TB PET/CT can visualize inflammatory pathologies in joints throughout the body and PET measures can be extracted from joints examined by rheumatologic assessments. There was a moderate to strong correlation between TB PET quantitative measures and rheumatologic outcome measures.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Rheumatology
Camille Roubille, Amandine Coffy, Nathalie Rincheval, Maxime Dougados, Rene-Marc Flipo, Jean-Pierre Daures, Bernard Combe
Summary: This study explored the 10-year tolerability profile of glucocorticoids (GC) use in patients with early RA, finding that patients with the highest cumulative exposure of GC had the highest risk of severe outcomes. The risk associated with GC treatment increased over time, indicating a long-term impact of low-dose GC treatment.
Article
Medicine, General & Internal
Jiahui Qian, Emily Banks, Kristine Macartney, Anita Elizabeth Heywood, Marissa Nichole Lassere, Bette Liu
Summary: The use of systemic corticosteroids is associated with an increased risk of herpes zoster, with higher doses leading to greater risk. The risk peaks in the month following a single prescription but returns to baseline levels by the third month.
MAYO CLINIC PROCEEDINGS
(2021)
Article
Rheumatology
Beth Wallace, Meriah N. Moore, Andrew C. Heisler, Lutfiyya N. Muhammad, Jing Song, Daniel J. Clauw, Clifton O. Bingham, Marcy B. Bolster, Wendy Marder, Tuhina Neogi, Alyssa Wohlfahrt, Dorothy D. Dunlop, Yvonne C. Lee
Summary: High fibromyalgianess is associated with persistent glucocorticoid use independent of inflammatory activity. Participants with high/very high baseline fibromyalgianess were more likely to be taking prednisone at follow-up relative to those with low fibromyalgianess.
Article
Medicine, General & Internal
Ji-Won Kim, Ju-Yang Jung, Hyoun-Ah Kim, Chang-Hee Suh
Summary: This study found that the impact of low-dose glucocorticoids on bone mineral density in patients with rheumatoid arthritis was not significant, while the disease activity index was a key factor affecting changes in bone density.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Rheumatology
John G. Hanly, Lynn Lethbridge
Summary: Over the past 20 years, the use of disease-modifying antirheumatic drugs (DMARDs) and biologics has increased in older adults with rheumatoid arthritis (RA), while the use of corticosteroids (CS) has remained consistent. Further efforts are needed to minimize the use of CS in the long-term pharmacological management of RA.
JOURNAL OF RHEUMATOLOGY
(2021)
Review
Medicine, General & Internal
Tao Pu, Yu Ni, Pan-hong Li, Dan Yu, Qiong Yu, Li-mei Yu
Summary: Methotrexate is an effective medication for treating rheumatoid arthritis and other diseases, but it can cause severe pancytopenia complications in dialysis patients. Supportive treatment and blood purification can help patients recover.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
(2022)
Review
Chemistry, Multidisciplinary
Yan Zhu, Tianjiao Zhao, Min Liu, Shuya Wang, Saili Liu, Yunrong Yang, Yuqi Yang, Yayun Nan, Qiong Huang, Kelong Ai
Summary: Rheumatoid arthritis (RA) is a disease with a significant medical burden and a tumor-like microenvironment. Traditional anti-inflammatory therapies are hindered by the buffer barrier of the RA microenvironment, while nanomaterials offer a potential solution by interfering with multiple pathogenic factors and achieving precise treatment. Recent advances in nanomaterials have greatly improved the therapeutic effect and reduced side effects in RA treatment.
Article
Immunology
Jia Wang, Sheng-Xiao Zhang, Jia-Song Chang, Ting Cheng, Xiao-Jing Jiang, Qin-Yi Su, Jia-Qi Zhang, Jing Luo, Xiao-Feng Li
Summary: This study investigated the status of CD4(+) Tregs and the effects of low-dose IL-2 therapy in patients with refractory rheumatoid arthritis (RA). The results showed that a decrease in the absolute number of CD4 Tregs, rather than an increase in Th17 cells, contributed to an imbalance and high disease activity. Low-dose IL-2 selectively increased CD4 Tregs and rebalanced the ratio of Th17 and CD4 Tregs, leading to symptom remission without side effects.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Elise Descamps, Clemence Gorlier, Sebastien Ottaviani, Elisabeth Palazzo, Philippe Dieude, Marine Forien
Summary: The study found that about one-third of RA patients requiring bDMARDs treatment had oral infections, with 20.9% having dental infections and 14.8% having sinusitis. Active smoking was associated with an increased risk of oral infection, while methotrexate was associated with a reduced risk.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Rheumatology
Ho So, Tsz On Lam, Huan Meng, Steven Ho Man Lam, Lai-Shan Tam
Summary: The use of glucocorticoids (GC) increases the risk of cardiovascular events (CVE) in rheumatoid arthritis (RA) patients, but there is controversy regarding the threshold dose and duration of GC use that will increase the CVE rate. This study found that a daily prednisolone dose ≥5 mg significantly increased the risk of CVE, while a daily dose below 5 mg was not associated with CVE risk.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Pharmacology & Pharmacy
Man Li, Guoqiang Wang, Yinyin Yan, Mengyuan Jiang, Zhirong Wang, Zhenqiang Zhang, Xiangxiang Wu, Huahui Zeng
Summary: In this study, a novel nanoparticle platform was developed to deliver TP for synergistic treatment of rheumatoid arthritis and inhibition of oxidative stress. Compared to traditional triptolide, TP-VP NPs effectively improved arthritis symptoms and significantly reduced multi-organ toxicity.
Review
Rheumatology
Maria Chiara Maccarone, Daniele Coraci, Gianluca Regazzo, Nicola Sarandria, Anna Scanu, Stefano Masiero
Summary: Long COVID syndrome refers to the new, returning, or persistent symptoms after the initial SARS-CoV-2 infection. Musculoskeletal symptoms have a significant impact on the quality of life in many patients. A literature review was conducted to explore the evolution of musculoskeletal symptoms in Long COVID syndrome. The findings highlight the need for interdisciplinary management and timely rehabilitative interventions.
Review
Rheumatology
Alexis Mathian, Renaud Felten, Marta E. Alarcon-Riquelme, Antony Psarras, Philippe Mertz, Francois Chasset, Edward M. Vital, Laurent Arnaud
Summary: Improved understanding of the molecular basis of innate immunity has led to the recognition of type I interferons (IFNs) as key mediators in the development of immunemediated inflammatory diseases (IMIDs). Pharmacological targeting of IFNs and their downstream signaling pathways, such as JAK1 and Tyk2, holds promise for the treatment of IMIDs.
Review
Rheumatology
Marie Robert, Marc Scherlinger
Summary: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune dysregulation and organ injury, involving the active role of platelets in the pathogenesis and disease progression. Platelets in SLE patients show intrinsic differences and can perpetuate inflammation by interacting with immune cells, thereby participating in organ damage and heightened cardiovascular mortality.
Review
Rheumatology
Jean Sibilia, Fabrice Berna, Jean-Gerard Bloch, Marc Scherlinger
Summary: Mind-body practices, such as mindfulness meditation, yoga, and Tai Chi, show promise in improving patient-reported outcomes in chronic rheumatic diseases, but their impact on inflammation and structural progression remains unclear.
Review
Rheumatology
Anne Tournadre, Marine Beauger
Summary: Obesity alters the characteristics of adipose tissue, leading to chronic low-grade inflammation, increased risk of chronic inflammatory diseases, and impact on treatment efficacy. Dietary and weight adjustments have a positive effect on improving inflammatory rheumatic diseases.
Article
Rheumatology
Romain Fore, Eric Liozon, Stephanie Dumonteil, Thomas Sene, Emmanuel Heron, Valentin Lacombe, Mathilde Leclercq, Julie Magnant, Clement Beuvon, Alexis Regent, Donatienne de Mornac, Maxime Samson, Perrine Smets, Jean-Francois Alexandra, Brigitte Granel, Pierre-Yves Robert, Muhammad Faiz Curumthaullee, Simon Parreau, Sylvain Palat, Holy Bezanahary, Kim Heang Ly, Anne-Laure Fauchais, Guillaume Gondran
Summary: This study aimed to evaluate whether the use of intravenous pulse of methylprednisolone reduces the risk of bilateral visual ischemia in patients with giant cell arteritis. The results showed no significant difference in the incidence of bilateral visual ischemia between the group receiving intravenous pulse of methylprednisolone and the group receiving direct prednisone.
Review
Rheumatology
Florent Eymard, Judith Aron-Wisnewsky
Summary: Obesity is a major modifiable risk factor for osteoarthritis (OA) and is associated with poorer outcomes in terms of pain, functional limitations, and response to treatments. Bariatric surgery (BS) can significantly reduce symptoms and improve function in patients with symptomatic knee OA, but its impact on long-term complications of arthroplasties appears to be disappointing. Overall, BS shows promise in reducing OA symptoms and potentially slowing disease progression.
Review
Rheumatology
Georges Marouna, Christina Fissouna, Marina Villaverde, Jean-Marc Brondelloa, Yves-Marie Pers
Summary: Recent discoveries have shown that the presence of senescent cells in osteoarticular tissues plays a crucial role in the development of osteoarthritis (OA). However, the senescence-regulatory factors associated with OA still need to be identified. Additionally, there is a lack of diagnostic and prognostic biomarkers currently used in clinics to evaluate OA patients. In the future, detecting senescence-regulatory biomarkers in patient fluids, along with imaging and clinical examination, could become a promising method for diagnosing, monitoring, assessing progression, and predicting prognosis in OA patients.
Article
Rheumatology
Patrick Yousif, Vicky Nahra, Muhammad A. Khan, Marina Magrey
Summary: Axial psoriatic arthritis (axPsA) has unique clinical and radiographic features compared to axial spondyloarthritis (axSpA). IL-23 inhibitors may be effective in treating axPsA, but further clinical trials are needed. Developing classification criteria and assessment tools for axPsA is also necessary.
Review
Rheumatology
Baptiste Gerard, Florian Bailly, Anne-Priscille Trouvin
Summary: This review aims to critically evaluate the effectiveness and safety of pharmacological treatments for chronic pain in rheumatic diseases, providing guidance for clinicians in selecting appropriate treatment options. The recommended pharmacological treatments vary depending on the specific rheumatic disease.